High mobility group box 1 (HMGB1), which has become one of the most intriguing molecules in inflammatory disorders and cancers and with which ligand-activated peroxisome proliferator-activated receptors (PPARs) are highly associated, is considered as a therapeutic target. Of particular interest is the fact that certain PPAR ligands have demonstrated their potent anti-inflammatory activities and potential anticancer effects. In this review article we summarize recent experimental evidence that PPAR ligands function as suppressors that target biological actions of HMGB1, including intracellular expression, receptor signaling cascades, and extracellular secretion of HMGB1 in cell lines and/or animal models. We also propose the possible mechanisms underlying PPAR involvement in inflammatory disorders and discuss the future therapeutic value of PPAR ligands targeting HMGB1 molecule for cancer prevention and treatment.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2aeuSuE
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Abstract Bone homeostasis is maintained by a balance between resorption of the bone matrix and its replacement by new bone. Osteoclasts p...
-
Abstract Continuous tooth replacement is common for tetrapods, but some groups of acrodont lepidosaurs have lost the ability to replace th...
-
ACS Nano DOI: 10.1021/acsnano.6b07537 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2i580k9 via...
-
Abstract Background Histamine intolerance is thought to trigger manifold clinical symptoms after ingesting histamine-rich food due to re...
-
Editorial introductions No abstract available Editorial: COVID-19 in older persons: the role of nutrition No abstract available A year with ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου